Gamma interferon administration to patients with atopic dermatitis inhibits fibrinolysis and elevates C1 inhibitor.
Recombinant human gamma interferon was used to treat 10 atopic dermatitis patients. Recombinant gamma interferon was administered weekly for three consecutive days at 50 microg/M2 SQ for four weeks. All patients' dermatitis improved with recombinant gamma interferon therapy and plasma tumor necrosis factor-alpha levels rose with treatment. Recombinant gamma interferon treatment positively correlated with reduced total plasma fibrinolysis as measured by the fibrin lysis plate, plasmin-alpha2antiplasmin complexes, and tissue type plasminogen activator levels. Accordingly, plasminogen activator inhibitor levels increased. Treatment also was associated with a transient increase in thrombin-antithrombin III complexes. Recombinant gamma interferon resulted in a significant increase in C1 inhibitor antigen but not activity. Plasma prekallikrein, high molecular weight kininogen, and factor XII levels were not decreased. However, 5 of the 10 atopic dermatitis patients before therapy had circulating cleaved plasma high molecular weight kininogen detected on immunoblot, indicating prior kallikrein formation. The cleaved, circulating plasma high molecular weight kininogen disappeared in four out of the five original patients who were reexamined at one year after treatment. These combined data indicated that recombinant gamma interferon treatment reduced total plasma fibrinolysis. In untreated atopic dermatitis, circulating cleaved high molecular weight kininogen also may be a presenting manifestation.
Department of Medicine, University School of Medicine, Krakow, Poland.
J
J
Musial
P
P
Gluszko
A
A
Undas
F
F
Mahdi
S
S
Kang
A
A
Szczeklik
A H
AH
Schmaier
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000097:blood; D003172:Complement C1 / Q000276:immunology*; D003876:Dermatitis, Atopic / Q000097:blood* / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage*; D008297:Male; D011994:Recombinant Proteins
D000906:Antibodies; D003172:Complement C1; D011994:Recombinant Proteins; D007371:Interferon-gamma